Group 1 - Omeros Corporation held its Q1 2025 earnings conference call on May 15, 2025, at 4:30 PM ET [1] - The call included participants from the company such as the Chairman & CEO, Chief Accounting Officer, and Chief Commercial Officer [1][6] - The call was recorded and a replay will be available on the company's website for one week [1] Group 2 - Jennifer Williams, representing Investor Relations, opened the call and thanked participants for joining [2][3] - Forward-looking statements were mentioned, indicating that they are based on management's beliefs and expectations and are subject to change [4] - The call was turned over to Dr. Gregory Demopulos, the Chairman and CEO, who was joined by other key executives [5][6]

Financial Data and Key Metrics Changes - Zometica reported total revenue of $6.5 million for Q1 2025, reflecting a 4% increase year-over-year, marking the seventeenth consecutive quarter of record revenue growth [5][14] - Gross margin improved to 68%, up from 66% in Q1 2024 [15] - The net loss for the quarter was $63.8 million, significantly higher than the net loss of $9.2 million in the prior year, primarily due to a $55.8 million non-cash impairment expense [16][17] Business Line Data and Key Metrics Changes - Revenue from the Therapeutic Devices segment was $5.9 million, while the Diagnostics segment generated approximately $600,000, a decrease of 25% [15] - Consumables revenue reached $4.5 million, a 13% increase year-over-year, representing about 70% of total revenue [14][15] - The TruForma platform saw a 41% year-over-year growth, driven by the launch of new assays [8] Market Data and Key Metrics Changes - International revenue grew approximately 32% year-over-year, indicating strong performance in new international markets [8] - The equine market expansion is a key focus, with new product launches aimed at increasing adoption and utilization [6][19] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven and GAAP profitability through operational efficiencies and cost reductions [11][20] - Key growth strategies include expanding into the equine market, international market growth, and enhancing the TruForma platform with new assays [19][20] - Zometica is also focusing on optimizing its infrastructure to support growth and reduce costs [11][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in 2025, particularly in the equine market and international expansion [18][19] - The company is committed to reducing cash operating expenses and improving overall cost structure [12][21] - Management highlighted the importance of achieving cash flow profitability to support stock price appreciation [50][51] Other Important Information - The company relocated its headquarters to a smaller facility, which is expected to reduce overhead costs by over $200,000 annually [11] - Zometica has no debt and ended the quarter with $64.6 million in cash and cash equivalents [17][24] Q&A Session All Questions and Answers Question: Why have management options not been repriced or new options issued, instead of salary? - Management believes it is inappropriate to change the strike price of options and continues to issue option grants to employees [27] Question: Why are marketing costs much higher than the industry averages? - Marketing costs are high due to the nature of introducing new products to the market, which requires significant investment [28][30] Question: Are you looking to expand into retail vet stores? - Currently, the company sells one product line through online channels and has limited presence in brick-and-mortar stores [31] Question: Is there a strategy for getting institutional coverage, investment banking relations, and so on? - Institutional coverage is challenging due to the stock price being below a dollar, and the company is not prioritizing this at the moment [35] Question: Are you using or planning on using AI to expand the number and rate of discovery of new assays for TruForma? - The company is not currently using AI for this purpose but has a good cadence of assays under consideration for development [39] Question: How profitable has the new Vetigel product been? - The Vetigel product has favorable margins, and the company is focused on acquiring consumable product lines that can leverage the existing client base [41][42] Question: Why are you focusing so heavily on equine when it's only 5% the size of the domestic animal market? - The equine market has high penetration and demand for the company's products, justifying the focus [43] Question: What is the status of TruView? - The TruView platform is nearing completion for AI reporting and is expected to launch soon [45] Question: Do you plan on hiring a new CFO to replace Scott? - The current Vice President of Finance is doing a good job, and hiring a new CFO is not a priority at this time [46] Question: Are there any plans in place to try and increase the stock share price? - The company is focusing on internal growth and operational improvements to drive stock price appreciation [48][50] Question: What is the status of the cancer assay? - The cancer assay concept has been abandoned as it was determined not to be viable [58] Question: Have the tariffs affected the international expansion at all? - Tariffs have had a minor impact, but the company expects to continue expanding its international market presence [60][62]

Core Viewpoint - Ondas Holdings Inc. is conducting its Q1 2025 earnings conference call, indicating a focus on financial performance and strategic direction for the upcoming quarter [1]. Company Participants - The call features key executives including Eric Brock (Chairman, President, and CEO), Neil Laird (Interim CFO), Oshri Lugassy (Co-CEO, Autonomous Systems), and Markus Nottelmann (CEO, Ondas Networks) [1]. Conference Call Structure - The conference call is structured to allow participants to listen only, with an emphasis on forward-looking statements that may contain risks and uncertainties [2]. - The company has provided a reconciliation of non-GAAP financial measures to GAAP measures, highlighting the importance of these metrics for understanding business trends [3].

Capital Southwest (NASDAQ:CSWC) Q4 2025 Earnings Conference Call May 15, 2025 11:00 AM ET Company Participants Amy Baker - EVP Accounting Michael Sarner - President and CEO Josh Weinstein - Senior MD and Chief Investment Officer Chris Rehberger - CFO, Treasurer and Secretary Conference Call Participants Mickey Schleien - Ladenburg Corey Johnson - UBS Erik Zwick - Lucid Capital Markets Robert Dodd - Raymond James Operator Thank you for joining today's Capital Southwest Fourth Quarter Fiscal Year 2025 Earning ...

Core Viewpoint - Gauzy Ltd. is conducting its Q1 2025 earnings conference call, indicating a focus on financial performance and future projections [1]. Group 1: Company Overview - The conference call is hosted by Gauzy's CEO Eyal Peso and CFO Meir Peleg, highlighting the leadership's involvement in discussing the company's performance [3]. - The call is recorded and allocated one hour for prepared remarks and Q&A, suggesting a structured approach to investor communication [1]. Group 2: Financial Statements and Projections - Management will be making forward-looking statements based on current expectations and beliefs, which are inherently uncertain [3]. - Actual results may differ materially from forward-looking statements due to various risks and uncertainties discussed in the earnings news release [4].

Core Points - flyExclusive reported its first quarter 2025 financial results, which were announced after market close [2] - The company continues to undergo a transformation that began in 2024, with benefits now becoming evident [5] Financial Information - The company filed its Form 10-Q for the quarter ended March 31, 2025, which includes important disclosures and reconciliations of non-GAAP information [2][3] - Non-GAAP information will be discussed during the earnings call, with a reference to the SEC filings for detailed reconciliations [3] Leadership and Participation - The earnings call featured key participants including Jim Segrave, the Founder and CEO, and Brad Garner, the CFO [2][4] - Kyle Nagarkar from Solebury Strategic Communications facilitated the call [1]

Group 1 - Nutex Health Inc. held its Q1 2025 earnings conference call on May 14, 2025, at 10:30 AM ET [1] - The call was moderated by Jennifer Rodriguez, the Investor Relations Manager, and included key leaders such as Dr. Tom Vo, Jon Bates, Warren Hosseinion, and Josh DeTillio [3][4] - The discussion aimed to review the company's performance and outline future plans, with a focus on financial results, operational progress, and strategic direction [3][4] Group 2 - The conference call included forward-looking statements based on management's current expectations, which are subject to risks and uncertainties [5] - Non-GAAP measures like adjusted EBITDA were mentioned, with reconciliations available in the press release and Form 10-Q [5]

Core Viewpoint - Lucid Diagnostics Inc. provided a business update and financial results for Q1 2025 during a conference call, highlighting key developments and future outlooks for the company [1][2][3]. Group 1: Company Overview - The conference call featured key participants including Matt Riley (Senior Director of Investor Relations), Dr. Lishan Aklog (Chairman and CEO), and Dennis McGrath (CFO) [1][3]. - The press release detailing the business update and financial results is accessible on Lucid's official website [3]. Group 2: Financial Results - Specific financial metrics and performance indicators were likely discussed during the call, although detailed figures are not provided in the available text [1][2][3].

Core Viewpoint - Hyliion Holdings Corp. is conducting its Q1 2025 earnings conference call, indicating a focus on financial performance and future business outlook [1][3]. Group 1: Company Overview - The conference call features key executives including CEO Thomas Healy and CFO Jon Panzer, highlighting the leadership team's involvement in discussing the company's performance [3]. - A slide presentation is available on Hyliion's Investor Relations website, providing additional context and data for investors [3]. Group 2: Forward-Looking Statements - The company will make forward-looking statements regarding its business outlook, which are based on current expectations and assumptions, subject to risks and uncertainties [4]. - Factors that could cause actual results to differ from these forward-looking statements are acknowledged, emphasizing the importance of caution in interpreting these predictions [4].

Group 1 - NETSOL Technologies, Inc. held its Q1 2025 Earnings Conference Call on May 14, 2025, featuring key executives including the CEO and CFO [1][2] - The call included a review of the company's business highlights and financial results, followed by a Q&A session [2] - Management provided necessary cautions regarding forward-looking statements, indicating that actual results may differ from forecasts [3] Group 2 - The company discussed certain non-GAAP measures during the call, with a reconciliation of these measures to the most comparable GAAP measures provided in the press release [4]